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Abstract
Background: In the UK, type 2 diabetes mellitus (T2D) is largely managed in primary care. Delay in the
intensification to injectable therapy, a form of clinical inertia, is associated with worse glycaemic control. UK general
practice is highly computerised, with care being recorded on computerised medical record systems; this allows for
quantitative analysis of clinical care but not of the underpinning decision-making process. The aim of this study is
to investigate perceptions of patients and clinicians in primary care on the initiation of injectable therapies in T2D,
and the context within which those decisions are made.
Methods: This is a mixed methods study, taking a “realist evaluation” approach. The qualitative components
comprise focus groups, interviews, and video recordings of simulated surgeries; the quantitative analysis: an
overview of participating practices, elements of the video recording, and an online survey. We will recruit primary
care clinicians (general practitioners and nurses) and patients from a representative sample of practices within the
Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network. Participants will be
patients with T2D, and primary care clinicians. Focus groups and semi-structured interviews will be recorded,
transcribed verbatim and analysed using Framework Analysis. The simulated surgeries will include cases that
might be escalated to injectable therapy. The consultation will be reviewed using the Calgary-Cambridge model
to assess communication and determination of adherence to national prescribing guidelines. We will conduct
multi-channel video recording including screen capture, clinician and patient facial expressions, wide angle view
of the consultation, and the computerised medical record screen. This allows annotation and qualitative analysis
of the video recordings, and statistical analyses for the quantitative data. We will also conduct an online survey of
primary care clinicians’ attitudes to, and perceptions of, initiation of injectable therapies, which will be analysed
using summary statistics.
Discussion: Results aim to provide a detailed insight into the dynamic two-way decision-making process
underpinning use of injectable therapy for T2D. The study will provide insights into clinical practice and enable
the development of training, interventions and guidelines that may facilitate, where appropriate, the
intensification to injectable therapy.
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Background
Type 2 diabetes (T2D) is a major problem for many
health care systems [1–8]. The World Health Organisa-
tion (WHO) has estimated that there are approximately
422 million people in the world with T2D [1]. Following
analyses of the Framingham study in the 1970s it
became clear that T2D is a major risk factor for macro-
vascular disease (including myocardial infarction and
stroke), and studies since have demonstrated that
macrovascular risk increases with worsening glycaemic
control [9, 10]. Diabetes is also associated with an
increased risk of microvascular complications which in-
cludes diabetic retinopathy, neuropathy, and renal
disease [11]. Several landmark trials have demonstrated
that risk for both microvascular and macrovascular com-
plications of diabetes can be reduced by improving blood
glucose control [12–15].
National and international guidelines have provided
targets for optimum glycaemic control, which have been
established through observational evidence and clinical
trials [16–22]. However, adequate glycaemic control is
difficult to achieve for a significant proportion of people
with T2D. In a large-scale European study, real-world
diabetes care was compared against the glycaemic tar-
gets produced by the American Diabetes Association
(ADA) and European Association for the Study of Dia-
betes (EASD), and found that only 53.6% of people with
T2D achieved adequate glycaemic control, with consid-
erable variation between countries [23].
In the UK, T2D is largely managed in primary care, re-
inforced by pay-for-performance (P4P) in general practi-
tioners’ contracts [2, 3, 24] - a scheme called the Quality
and Outcomes Framework (QOF). UK general practice
consultations are recorded into computerised medical
record (CMR) systems which actively flag whether a pa-
tient with T2D is at target. Rewards paid through the
P4P system, QOF, are solely based on information
recorded in CMR systems. These computerised systems
record the diagnosis of T2D and link to pathology ser-
vices allowing transfer of glycated haemoglobin (HbA1c)
data to the individual’s medical records. CMR systems
also record all the prescriptions issued in primary care.
Additionally, most brands of CMR systems prompt the
primary care clinician at every consultation if a person
with T2D is not at their glycaemic target. Therefore,
every time a person with T2D presents to their general
practitioner (GP) or other primary care clinician, the
clinician can readily tell if they are at target, and gener-
ally with one mouse click, whether they are receiving
maximal oral therapy [25].
QOF remuneration targets for T2D include optimising
the number of people below set glycaemic thresholds.
CMR based interventions are known to generally im-
prove care [25] and the introduction of these P4P targets
appear to have improved glycaemic control and reduced
inequalities in T2D management [26, 27]. However, it is
difficult to disentangle these effects from other quality
improvement initiatives.
One component of suboptimal management is delay
in intensification of therapy. Delays in intensification
occur at each stage of treatment: from diagnosis to first
oral medication, to second and third oral medications,
to the initiation of injectable therapies and escalation of
injectable therapies once initiated [28]. These delays
termed “therapeutic inertia” or, more commonly “clinical
inertia” [29], are associated with impaired glycaemic
control and concomitant complications including micro-
vascular (e.g. retinopathy, chronic kidney disease) and
macrovascular diseases (e.g. heart failure, stroke) [30].
Despite improved glycaemic control following the use of
injectable therapy, drawbacks of insulin include weight
gain, and severe hypoglycaemia and increased risk of
death [31, 32], whilst glucagon-like peptide 1 receptor
agonists (GLP-1 RAs) have been linked to gastrointes-
tinal symptoms such as nausea, vomiting, and diarrhoea
[33], which may deter people from using them. Other
barriers to starting injectable therapy include the indi-
vidual struggling to acknowledge that their diabetes
has progressed, anxiety and fear of pain from inject-
ing, the need to regularly test blood glucose levels,
and the difficulty incorporating injecting during work-
ing hours [34–36].
Clinician, patient, and health service factors have
been identified as contributing to clinical inertia
[37–44]. However, an improved understanding of the
specific patient, clinician, and health service factors
that influence clinical inertia is urgently needed to
facilitate improved glycaemic control and health out-
comes in people with T2D.
Aims and objectives
The aim of this study is to explore the perceptions of pa-
tients and clinicians regarding the initiation of injectable
therapies: insulin and GLP-1 RAs, and to describe the
context within which these decisions are made.
The primary objectives of this study are:
 To explore the attitudes and experiences of patients
with T2D and primary care clinicians (GPs and
nurses) of barriers and facilitators to initiating
injectable therapies.
 To describe the context and processes in which
injectable therapy initiation would take place; in
particular how computerised prompts are managed.
 To describe any consensus or discrepancies within
and between clinicians and patients about attitudes
to intensification to injectable therapies.
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Methods
Study design and setting
This study combines qualitative and quantitative methods,
and should be regarded as a mixed methods study [45–
47]. It will be run within the Royal College of General
Practitioners (RCGP) Research and Surveillance Centre
(RSC) sentinel network of general practices (35, 36). The
qualitative methods comprise focus groups that will be
carried out with a sample of practices. Interviews will be
used if patients or clinicians are unable or uncomfortable
with participating in focus groups. The subsequent quanti-
tative component will include a comparison of initial
themes on injectable therapy drawn from an earlier phase
of the study, with other practices in the network via a sur-
vey to explore consensus. We will also carry out a video
study to provide quantitative data on key prompts/triggers
for the initiation of injectable therapy raised during a con-
sultation with a simulated T2D patient.
We will recruit participants from volunteer practices
within the RCGP RSC network, [48, 49]; our aim is to
recruit practices that are representative of the network.
The RCGP RSC data have been used extensively for dia-
betes research, and although there are limitations in case
finding, recording of pathology results, and in recording
of therapies, the network has good data quality and is
largely nationally representative [48].
The research project will be run in three phases: Phase
1: Focus groups and interviews; Phase 2: Video record-
ing of simulated surgeries with follow-up focus groups;
and Phase 3: Survey, consensus exercise (Fig. 1). The
qualitative processes will follow the Consolidated
Criteria for Reporting Qualitative Research (COREQ)
checklist [50].
Philosophical approach
We have defined, a priori, critical realism as an overall
philosophical approach. This approach is appropriate
because the decisions to intensify therapy in the clinical
consultation are complex [51]. The Medical Research
Council framework for Complex Intervention includes
key elements of critical realism, in particular the need to
define the context and mechanism [52].
Realist evaluation
We will use Pawson and Tilley’s “realist evaluation” to
provide a lens through which to explore initiation of in-
jectable therapy [53]. Realist evaluations explore how
context interacts with a mechanism to produce an out-
come. In this study:
 The context is the management of a person with
T2D in primary care, where the primary care
clinician should take a holistic view of the benefit-
risk of any treatment option.
 The mechanism(s) are complex. There are evidence-
based guidelines about intensification of treatment
[54]; there are financial incentives to ensure that
patients achieve glycaemic control [27]; and prompts
that appear in the consultation [55].
 The outcome measure is the commencement of
injectable therapy, in accordance with National
Institute for Health and Care Excellence (NICE)
guidance [54].
Critical realism attempts to answer the questions
“What works, for whom, in what circumstances, in what
respects, and why?” [56]. Our focus groups and direct
observation of the clinical consultation (video of simu-
lated surgery), and our consensus exercise will set out to
explore these. This is in contrast to the traditional
approach used in interventional studies (such as rando-
mised controlled trials) which focus on whether an inter-
vention works or not, without in-depth consideration of
the context or analysis of the mechanisms [57].
Fig. 1 Overview of the study phases
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Theoretical framework – model of pathways to treatment
To help us interpret and understand the different path-
ways to initiating injectable therapy in people with T2D,
we will use the Model of Pathways to Treatment as a
theoretical framework [58]. This has previously been
used to explore different care pathways in cancer re-
search [59, 60], but has been little used in diabetes. The
model pinpoints five key time points, “events”, that
might occur before a health care professional starts
treatment in an individual. These events include, (1) an
individual identifying physical changes in the body; (2)
realising that these symptoms are abnormal and should
be discussed with a health care professional; (3) discuss-
ing concerns about the body changes with a health care
professional for the first time; (4) the time point at
which a diagnosis is made; and (5) commencement of
treatment. The time periods, “intervals”, that occur
between each event are factored into the model, as well
as “processes”, which take place within the intervals and
can trigger the successive event.
Sample selection
Participants will be purposively sampled to ensure that a
range of individual characteristics are represented within
the staff (years in practice, diabetes experience) and pa-
tient (diabetes duration, ethnicity, socioeconomic status)
focus groups [61]. Our sample will be restricted, for
travelling reasons, to within 50miles of our University
location. Effectively, this is to London and the southeast
of England. We will select practices that are broadly
similar to other general practices in England in terms of
size, prevalence of patients with T2D, their age, gender,
ethnicity, deprivation, glycaemic control and threshold
for prescribing injectable therapy. We report the sam-
pling methods in more detail in the following sections.
Data collection
Phase 1 – Focus groups and interviews
Phase 1 comprises separate focus groups, or interviews,
with patients and clinicians. We will conduct separate
focus groups for the different participating groups to
minimise response bias: (1) patients, and (2) primary
care clinicians.
Topics for the patient group will include:
(i) Views on initiating injectable therapy
(ii) Facilitators and barriers affecting initiation and
adherence to injectable therapy
(iii)Other factors that affect decision-making.
Clinician topics will be:
(i) Reflection on their personal decision-making
processes
(ii) Insights into barriers and facilitators to initiation
and adherence to injectable therapy.
Whilst interaction within focus groups may identify
themes that may not emerge in individual interviews
[62], we may have to offer interviews when participants
find focus groups daunting, or where there are difficul-
ties with scheduling. The focus groups will comprise six
to eight participants - the recommended number for this
method [63].
We plan to conduct two patient focus groups and two
practitioner focus groups. Within each study practice,
we will recruit patients with T2D who are naïve to in-
jectable therapy, and others who have prior experience
of GLP-1 RAs and/or of insulin. The moderator will
introduce the topics under discussion, monitor group
dynamics to ensure that all participants have the oppor-
tunity to share their views, are adequately represented,
and all topics are covered. A second moderator will be
present to take detailed notes of the discussion and help
the moderator keep to times. The focus groups will last
between 90 to 120min. The focus groups and interviews
will be recorded and transcribed verbatim [50].
Pilot focus groups will be conducted to inform the
interview schedules. One pilot focus group will be con-
ducted with clinicians, and another with T2D patients.
Participant inclusion criteria The following people will
be eligible for phase 1 of the study:
 Aged 18 years or older
 A recorded and physician-confirmed diagnosis T2D
 English speaking
 A registered patient with one of the participating
RCGP RSC practices.
Primary care clinicians will also be eligible for inclu-
sion if they are a GP or a practice nurse working at one
of the participating practices.
Phase 2 – a) Video-recorded simulated surgeries
We will conduct video-recorded simulated surgeries
with GPs and follow-up focus groups. These will capture
the context within which escalation to injectable therapy
occurs. It will also provide direct observation of the
components of the clinical consultation that are not rou-
tinely recorded in CMRs, such as clinicians’ approach to-
wards care (shared or non-shared decision-making with
patients). We hope to reproduce the prompts and access
to guidelines that GPs generally see.
Six GPs and three actors will participate in a diabetes
clinic run at their practices. Actors will be accessed
through the RCGP Clinical Skills Assessment (CSA), as
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they have experience in simulated surgeries within a pri-
mary care environment, and through our contacts with
patients with T2D. Concepts communicated by partici-
pants in Phase 1 will be used to inform scenarios
involving initiation of injectable therapy (insulin and
GLP-1 RAs), which will then be given to the actors.
The scenarios will include: (1) a simulated patient
where injectable therapy is probably not needed
(Additional file 1); (2) a simulated patient who should be
initiated on insulin (Additional file 2); and (3) a simu-
lated patient who should be initiated on a GLP-1 RA
(Additional file 3).
The actors will present their scenario to each of the
clinicians in rotation, which will be video-recorded using
the Activity Log File Aggregation (ALFA) toolkit [64].
The booked duration of each consultation will be 20
min; they will be stopped at 22 min. Most general prac-
tice diabetes clinics allow 20 min for consultations,
though some follow-up is done in 10 min.
The ALFA toolkit is a multi-channel video method to
capture the precise observation of the clinical consult-
ation such as verbal and non-verbal cues, and the impact
of the computer, through capturing different streams of
data [64, 65]. The ALFA toolkit records four streams of
data; (1) clinician’s upper body, (2) patient’s upper body,
(3) wider angle capturing both patient and clinician, and
(4) the clinician’s computer screen. The videos will be
stored on encrypted and password protected hard drives.
b) Follow-up focus groups – including assessing consensus
statements
The GPs that take part in the simulated surgeries will be
asked to participate in a follow-up focus group to dis-
cuss the scenarios that were presented to them. In
addition, we will present the GPs with consensus state-
ments to explore where there is a consensus or disagree-
ment about the facilitators and barriers to intensification
of treatment to injectable therapy [66]. These statements
will be generated using the findings of the focus groups
in phase 1. Such a process often assists to produce rec-
ommendations or issue statements that can be used for
understanding the current state of care and assist in
related policy development or process improvement
[67–70]. The consensus statements will be subjected to
an expert panel review (the GPs in this instance) during
which they will indicate the appropriateness of each
statement using a Likert scale similar to that used in
Delphi studies [71]. The feedback will be used to revise
the consensus statements and sent for a further round of
consensus to the same expert panel.
Participant inclusion criteria Up to six GPs working at
one of the participating practices will participate in
phase 2, and also three actors accessed via the RCGP
CSA and through contact with patients with T2D.
Phase 3 – Quantitative surveys /consensus exercise
We will use the findings from phases 1 and 2 (Round 1)
to develop an online survey for clinicians, to capture the
degree of consensus with our phase 1 and 2 findings
(Round 2) (Fig. 2). The surveys will include statements
for respondents to agree or disagree with. There will also
be an opportunity for the respondents to explain why
they agree or disagree with a statement.
 Generating consensus statements: This will be a
selective round where the information captured in
the research so far will be converted into a set of
consensus statements (Round 2). The information
captured from patients will be used to formulate a
set of consensus statements for representing patient
views, whilst information captured from the
clinicians will be used to formulate a similar set of
statements representing the views of clinicians.
These consensus statements will be presented to the
GPs during the follow-up focus groups in Phase 2.
The clinicians will be expected to indicate the
appropriateness of each of the statements using a 7
point Likert scale (Round 2).
 Looking for agreement, equivocation or
disagreement with the consensus statements: During
this final round the statements generated will be
analysed and results will be presented to the
clinicians as an online report (and survey to collect
opinions about the results) (Round 3). This will be
carried out in parallel to phase 3. For each of the
statements, we will indicate if the panel of clinicians
in round 1 were in agreement, disagreement or
equivocal. During the presentations, the clinicians
will be invited to express their opinion about the
various levels of agreement assigned to the
statements. In cases, where the majority of
statements are not acceptable to the panel, we will
consider conducting an additional round of
consensus after revising the statements.
 This report will be shared with clinicians during the
final round of the consensus process whereby the
clinicians will be invited to suggest possible reasons
for the any disagreements expressed during the
evolution of the consensus document (Round 3).
Participant inclusion criteria Experts that have a sub-
stantial amount of experience caring for people with
T2D in the primary care setting (Round 2). We will also
involve clinicians in the wider RCGP RSC network to
explore whether the consensus feedback is relatable to
their primary care setting (Round 3).
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Data analysis
Phase 1 – Focus groups and interviews
We will use Framework Analysis, exploring previously
identified themes from existing literature (deductive ana-
lysis), as well as new concepts that might emerge during
the data collection process (inductive analysis) [72].
This analysis involves a five-step process: (1) familiar-
isation; (2) identifying a thematic framework; (3) index-
ing; (4) charting; and (5) mapping and interpretation
[73]. In the first step (1), the analyst will read the tran-
scripts, reflect on the research question, and keep notes
of potential ideas and recurring concepts. Then (2), the
analyst will use a priori knowledge of the literature as
well as the concepts from the first step to create a
framework/index to sort the new material. This is ex-
pected to be a descriptive list of concepts initially, which
will be refined to represent the diversity, centrality, and
dynamics of participants’ attitudes. Once this framework
has been developed, (3) it will be applied systematically
to the data, using a numerical system that will link them
directly to the index. Where a passage connects to more
than one theme, this will be noted. At this stage, a
second analyst will use the framework to test the trans-
parency of the method and compare his assumptions
with the first analyst’s. Once this is completed, the in-
dexes will be used to create thematic charts (4), which
will include a refined summary of major subjects that
will have emerged. This will provide a more abstract
view of the data in preparation of the last step (5),
wherein the analyst will look and interpret the data
as a whole.
This approach has been applied extensively in policy
research [74, 75], to observe similarities, discrepancies,
and interrelationships among the data [76]. We will use
QSR NVivo 11 and Microsoft Excel software to organise
and analyse this data [77].
Phase 2 – Simulated surgeries and follow-up focus groups
The ALFA toolkit [64] will be used to collect
video-recorded data from the simulated surgeries. These
will be analysed via thematic coding using the themes
developed from the focus groups [78]. Since the ALFA
toolkit captures several streams of data, we will analyse
different aspects of the consultation: non-verbal
Fig. 2 Consensus process pathway
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communication of the patient and clinician, verbal com-
munication, and information that is entered onto the
computer.
Assessment of the consultation quality using the
Calgary-Cambridge model The Calgary-Cambridge
consultation model [79] will be used to appraise the
primary care clinicians’ consultation skills from the
simulated surgeries. This enables us to assess if there
has been shared understanding and decision-making
[80–83]. The Calgary-Cambridge consultation model has
five steps: (1) initiating the session; (2) gathering infor-
mation; (3) building the relationship; (4) explanation and
planning; and (5) closing the session. The Global Con-
sultation Rating Scale, based on the Calgary-Cambridge
will be used to assess the quality of communication [84].
Assessment of the interaction between the GP and
the simulated patient A checklist will be developed for
each simulated surgery to enable us to:
1. Highlight key prompts/triggers for action either in
the patient’s history or the simulated medical
record
2. Note whether these were stated or accessed during
the consultation;
3. Whether the prompts / triggers resulted in action;
4. To determine whether the outcome of the
consultation which would be anticipated if
guidelines were followed.
This will be carried out using expert reviewers. These
reviewers will first identify key triggers in the records or
history from the simulated patient which should trigger
action, in this case intensification of T2D therapy. These
will be identified by two expert reviewers, and any differ-
ences discussed. The videos will then be independently
reviewed by two experts to see if these triggers were
recognised, discussed, and actioned. This peer approach
will mirror similar methods used to assess multidiscip-
linary team meetings [85].
Phase 3 – Survey/consensus exercise
Summary statistics will be used to describe the popula-
tion of interest. We will report these as agreement, dis-
agreement or equivocation where there is a spread of
Likert scale responses for each statement.
Data collection and analysis for consensus building
The consensus building process will be integrated
with the focus group activities planned in the study.
This will be carried out in parallel to the three phases
described above.
Integration of the data from each study phase
As described above, the first phase of the study will in-
form the design of the second and third phases of the
study. The study will therefore, use a sequential explora-
tory design in which qualitative data will be collected
and analysed in the first instance, followed by the collec-
tion and analysis of quantitative data, and these will then
be integrated and interpreted [86].
Discussion: strengths and weaknesses
One of the strengths of the study is its representative-
ness. The RCGP RSC sentinel network provides access
to a nationally representative sample of real world evi-
dence (RWE) data. This can facilitate the development
of interventions that have real-world effectiveness [87].
What this study adds is a robust exploration from a
realist evaluative stance. The study aims to capture the
details of context and mechanism and how these com-
bine to affect outcome (in this case commencing inject-
able therapy for diabetes).
Our context is one where T2D is largely managed by
GPs and nurses in primary care. A registration based
system where one patient is seen in a single practice,
often by the same doctor or nurse for their diabetes care.
These general practices are highly computerised, and the
consultations will be recorded on the practice CMR sys-
tem. The CMR also allows all previous blood tests in-
cluding glycated haemoglobin to be readily visualised.
The mechanism for achieving change includes prompts
and guidance pointing out poor glycaemic control. These
reminders may nudge the clinician towards escalation of
treatment. There is also the P4P/QOF incentive to inten-
sify treatment and achieve glycaemic control and other in-
dicator standards. These factors are in addition to those
already described in the literature.
A weakness of the study is that as language is an im-
portant aspect of qualitative research, only English-
speaking individuals can participate. This means that
perceptions of people with different language may not
be explored. Whilst video is much used for training and
assessment in primary care, there are always concerns it
may interfere with the clinician-patient relationship.
However, research suggest that consultation behaviour is
little affected by awareness of video recording [64].
In summary, we will explore the topic of intensifica-
tion to injectable therapy using a triangulation of quali-
tative and quantitative research methods. The use of
video recorded simulated surgeries to explore themes
that were derived from focus groups is a novel approach,
but we feel necessary to capture information about con-
text and mechanise that may not emerge from the narra-
tive. This study will gain insight into the different
dimensions of highly context-dependent settings, in our
case general practice.
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Additional files
Additional file 1: Scenario and medical record of Patient 1 (John
Thompson). Scenario and medical record of Patient 1 (John Thompson)
(DOCX 14 kb)
Additional file 2: Scenario and medical record of Patient 2 (Jane Smith).
Scenario and medical record of Patient 2 (Jane Smith) (DOCX 14 kb)
Additional file 3: Scenario and medical record of Patient 3 (Gary Jones).
Scenario and medical record of Patient 3 (Gary Jones) (DOCX 14 kb)
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